BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Pfizer Inc. (PFE) Said to Weigh Purchase of Strides Arcolab Limited Agila Unit


1/15/2013 7:20:29 AM

Pfizer Inc. (PFE), the world’s largest drugmaker, is among companies weighing a purchase of the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd. (STR), said three people with knowledge of the matter. Pfizer began due diligence last week for a possible acquisition of the Bangalore-based company’s division known as Agila Specialties, the people said, asking not to be identified as the process is private. The unit may be valued at about $2 billion, two of the people said. Strides provides Pfizer with generic versions of off-patent drugs through a partnership announced in 2010. Agila has also drawn interest from Canonsburg, Pennsylvania-based Mylan Inc., Swiss drugmaker Novartis AG (NOVN), and Fresenius SE, which is based in Bad Homburg, Germany, two of the people said. A deal could be reached in the first quarter, they said. Large drugmakers are seeking acquisitions to offset a potential decline in revenue as U.S. patents expire. With drugs losing patent protection this year and last, New York-based Pfizer may lose as much as $2.75 billion in sales in 2013, data compiled by Bloomberg show. Strides rose as much as 3.9 percent to 1095 rupees in Mumbai today, the most since Dec. 24. Representatives for Pfizer, Mylan and Novartis declined to comment, while a spokesman for Strides didn’t respond to requests for comment. “As a market leader, Fresenius is very often brought into contact with companies that potentially may be for sale,” Fresenius spokesman Matthias Link said in an e-mail. He declined to comment on any potential deal with Strides. Strides started trying to sell Agila last year, three people with knowledge of the matter said in August. Agila, which makes cancer treatments and antibiotics, accounted for 74 percent of Strides’s earnings before interest, taxes, depreciation and amortization in the nine months through September, a company release from October shows.

Read at Bloomberg
Read at Nasdaq
Read at News Release
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->